Table 2.

Spearman’s correlations of CETP activity and PCSK9 levels with clinical and metabolic variables

	CETP		PCSK9
	r	P	r	P
CETP	1.000	–	0.256a	<0.0001
PCSK9	0.256a	<0.0001	1.000	–
Age	−0.088	0.063	0.045	0.346
BMI	0.020	0.679	0.052	0.268
SBP	0.208	<0.0001	0.123	0.022
DBP	0.129	0.016	0.085	0.112
Cholesterol	0.585	<0.0001	0.194	<0.0001
Triglycerides	0.491	<0.0001	0.210	<0.0001
LDL-C	0.412	<0.0001	0.179	<0.0001
HDL-C	0.134	0.004	0.109	0.021
ApoB100	0.494	<0.0001	0.194	<0.0001
ApoA1	−0.002	0.970	0.135	0.004
Glucose	0.186	<0.0001	0.215	<0.0001
LCAT	−0.251	<0.0001	−0.072	0.127
Lp particles number
Total VLDL	0.419	<0.0001	0.176	<0.0001
Large VLDL	0.411	<0.0001	0.160	0.001
Medium VLDL	0.413	<0.0001	0.172	<0.0001
Small VLDL	0.420	<0.000	0.177	<0.0001
Total LDL	0.300	<0.0001	0.134	0.004
Large LDL	0.246	<0.0001	0.093	0.049
Medium LDL	0.234	<0.0001	0.111	0.019
Small LDL	0.332	<0.0001	0.152	0.001
Total HDL	0.098	0.038	0.024	0.614
Large HDL	0.109	0.021	0.043	0.359
Medium HDL	−0.193	<0.0001	−0.044	0.356
Small HDL	0.241	<0.0001	0.071	0.136
Lp size
VLDL	−0.276	<0.0001	−0.114	0.015
LDL	−0.200	<0.0001	−0.107	0.023
HDL	−0.362	<0.0001	−0.104	0.027

^aAfter adjusting PCSK9 for age, gender, BMI, SBP, LDL-C, triglycerides and glucose, the Spearman’s correlation with CETP remained significant (r = 0.158, P = 0.003)

BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C LDL cholesterol, HDL-C HDL cholesterol